Breast Cancer Awareness, Education, and Screening Tips: What Every Woman Needs to Know

 ·  12 min read

Breast cancer is the most commonly diagnosed cancer among women in the United States. In 2024, the American Cancer Society estimated more than 310,000 new cases of invasive breast cancer would be diagnosed in women, along with roughly 56,000 cases of ductal carcinoma in situ.1 Despite decades of awareness campaigns, one in eight women in the United States will develop breast cancer at some point in her lifetime.2

October is Breast Cancer Awareness Month, and the sea of pink that accompanies it serves a real purpose; it normalizes the conversation. But awareness without education has limits. What saves lives is knowing when to be screened, understanding what puts you at higher risk, and being willing to push for answers when something feels wrong.

I have been in oncology for over 16 years. I have cared for patients across the full arc of cancer – from initial staging workup through active treatment, survivorship, and, for some, end of life. I have held hands in infusion chairs, answered questions in clinic hallways, and had the hard conversations that come with a new diagnosis. And I can tell you this: the patients who had the best outcomes were not the luckiest. They were the most informed. They knew what to watch for. They showed up for their mammograms. They did not wait to bring something to their provider’s attention.

This article is my attempt to give you that same foundation.

The Current Screening Guidelines

Breast cancer screening guidelines have shifted in recent years, and the changes can be confusing. Here is where the major organizations currently stand.

The American Cancer Society recommends that women with average breast cancer risk begin annual mammograms at age 40 and continue as long as they are in good health and expected to live at least 10 more years. Women between 40 and 44 have the option to start annual screening. Women 45 to 54 should get mammograms every year. Women 55 and older can transition to mammograms every two years, or continue annually.3

The U.S. Preventive Services Task Force updated its guidance in 2024 to recommend that all women begin biennial (every two year) mammography screening at age 40. This is a significant change from its previous recommendation of starting at 50, and it reflects growing evidence that starting earlier improves early detection, particularly for Black women, who are diagnosed at younger ages and with more aggressive subtypes.4

What does this mean for you? If you are 40 or older and have not had a mammogram in the past year or two, that is where to start. Talk to your primary care provider about which schedule makes sense for your health history and risk profile. The most important thing is that you start, and that you are consistent.

“All women should begin biennial (every two year) mammography screening at age 40.”

The U.S. Preventive Services Task Force, 2024

High-Risk Screening: When Average Guidelines Are Not Enough

Mammography guidelines designed for average-risk women are not always sufficient for women at elevated risk. If any of the following apply to you, you may need earlier screening, more frequent imaging, or supplemental MRI in addition to mammography.

Family history. Having a first-degree relative, such as a mother, sister, or daughter, with breast cancer increases your risk, particularly if she was diagnosed before menopause or had bilateral disease. Multiple affected relatives across generations raise risk further.2

BRCA1 or BRCA2 gene mutations. Women who carry pathogenic variants in BRCA1 or BRCA2 have a significantly elevated lifetime risk of breast cancer, as well as increased risk for ovarian cancer. If you have a family history that suggests hereditary breast and ovarian cancer syndrome, ask your provider about genetic counseling and testing. High-risk surveillance guidelines for BRCA carriers typically recommend annual mammography and annual breast MRI beginning at age 25 to 30, alternating every six months.5

Prior chest radiation. Women who received radiation to the chest between the ages of 10 and 30, such as those treated for Hodgkin lymphoma, have an increased breast cancer risk and should typically begin high-risk surveillance eight to ten years after the radiation, or by age 40, whichever comes first.6

Elevated lifetime risk based on risk assessment models. Tools such as the Tyrer-Cuzick model and the Gail model calculate estimated lifetime risk based on a combination of factors including family history, reproductive history, and breast density. Women with a calculated lifetime risk of 20% or greater generally qualify for supplemental MRI screening in addition to annual mammography.5

If you are unsure whether you fall into a high-risk category, ask your provider to calculate your lifetime risk. Many women who would benefit from high-risk screening have never been offered it simply because no one ran the numbers.

Breast Density: What Is It and Why It Matters

Breast density refers to the proportion of fibrous and glandular tissue relative to fatty tissue in the breast. It is determined by your mammogram, not by how your breasts feel. Dense breasts are both a risk factor for breast cancer and a factor that can make tumors harder to detect on a standard mammogram, because both dense tissue and tumors appear white on the image.7

Approximately 40% of women have dense breast tissue.7 In 2023, the FDA updated mammography reporting requirements to ensure that women are informed of their breast density after a mammogram. If your report says you have dense breasts, talk to your provider about whether supplemental screening, such as ultrasound or MRI, is appropriate for you.8

Signs and Symptoms: Know What to Watch For

Screening catches cancers before symptoms develop, which is why it matters so much. But screening is not perfect, and not every woman is up to date on her mammograms. Knowing what to watch for between screenings is part of an informed approach to your own health.

Contact your provider promptly if you notice any of the following:

  • A new lump or thickening in the breast or underarm area that does not go away after your menstrual cycle
  • A change in the size, shape, or contour of the breast
  • Skin changes on the breast, including dimpling, puckering, or a texture that resembles an orange peel
  • Nipple changes, including inversion (a nipple that was previously outward turning inward), nipple discharge that is bloody or occurring without squeezing, or scaling around the nipple
  • Persistent breast pain that is localized and does not follow your normal hormonal pattern
  • Warmth, redness, or swelling of the breast that is not explained by infection

Many of these symptoms have benign explanations. A lump is more likely to be a cyst or fibroadenoma than a cancer. But the only way to know is to have it evaluated. Do not wait, and do not let yourself be brushed off. If you feel like something is not right, be persistent.

What Happens If Something Is Found

Receiving a call that your mammogram is abnormal – a BI-RADS 4 or 5 finding, or a recommendation for additional imaging or biopsy is frightening. It does not mean you have cancer. The majority of biopsies return benign results. But you do need to follow through with the recommended workup.

The next steps after an abnormal mammogram typically include one or more of the following: diagnostic mammogram with additional views, breast ultrasound to characterize the finding further, or image-guided biopsy if the finding warrants tissue sampling. Your radiologist and breast care team will guide you through what is needed based on what they saw on the images.

If a biopsy is recommended, ask questions. Ask what the procedure involves, when results will be available, and who will call you with the pathology. Make sure you know who your point of contact is and how to reach them.

A Note on Breast Cancer in 2010 and in 2026

In 2010, I recorded a video on breast cancer education as part of my early commitment to sharing oncology knowledge with patients and the public. You can view that video on YouTube. The landscape has changed significantly since then – targeted therapies and immunotherapy have transformed treatment for many subtypes, genetic testing has become more widely accessible, and personalized medicine has changed what treatment looks like for HER2-positive and triple-negative breast cancers in particular.

What has not changed is the importance of early detection. A tumor found at stage I has a five-year relative survival rate that exceeds 99%. That number falls with each advancing stage. Screening and early intervention are still the most powerful tools we have.9

Risk Reduction: What the Evidence Supports

Some breast cancer risk factors, such as being female, getting older, and carrying certain gene variants, cannot be changed. But others can be modified. The evidence supports the following risk reduction strategies for women at average and elevated risk:

Maintain a healthy weight. Excess body fat, particularly after menopause, increases estrogen levels, which can promote the growth of hormone-receptor-positive breast cancers. Weight management is one of the most modifiable risk factors for postmenopausal breast cancer.10

Limit alcohol. Even modest alcohol consumption is associated with increased breast cancer risk. The risk increases with the amount consumed. The American Cancer Society recommends that women who drink limit themselves to no more than one drink per day.10

Exercise regularly. Physical activity, particularly aerobic exercise, is associated with reduced breast cancer risk, likely through multiple mechanisms including effects on hormone levels, inflammation, and immune function. Aim for at least 150 minutes per week of moderate-intensity activity.11

Breastfeed if possible. Women who breastfeed, particularly for longer durations, have a modestly lower risk of breast cancer. The protective effect is thought to be related to hormonal changes during lactation.12

Discuss hormone therapy and its current guidelines with your provider. Long-term use of combined estrogen-progestogen hormone therapy is associated with a small increased risk of breast cancer. If you are considering or currently using hormone therapy for menopausal symptoms, talk to your provider about your personal risk and what the evidence says about your specific situation.13

For women at high risk based on genetics or family history, chemoprevention options including tamoxifen, raloxifene, and aromatase inhibitors may be appropriate. These are conversations to have with an oncologist or gynecologist who specializes in breast cancer risk reduction.14

The Conversation I Want You to Have

This October, I want you to do one thing: schedule the appointment you have been putting off. If you are due for a mammogram, make the call today. If you are unsure whether you are in a high-risk category, ask your primary care provider to help you figure that out. If you have noticed something that has been nagging at you, stop waiting for it to go away on its own.

Breast cancer does not wait, and neither should you.

The oncology team of nurse practitioners, oncologists, breast surgeons, and genetic counselors is here to help you navigate whatever comes next. You do not have to have it all figured out before you make the call. You just have to make it.

References

All citations follow APA 7th edition format.

1.  American Cancer Society. (2024). Breast cancer facts & figures 2024. American Cancer Society.  https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf

2.  National Cancer Institute. (2024). Breast cancer risk in American women.  https://www.cancer.gov/types/breast/risk-fact-sheet/

3.  American Cancer Society. (2024). American Cancer Society recommendations for the early detection of breast cancer.  https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html

4.  U.S. Preventive Services Task Force. (2024). Breast cancer: Screening. JAMA, 331(22), 1918-1930.  https://jamanetwork.com/journals/jama/fullarticle/2826624

5.  Bevers, T. B., Helvie, M., Bonaccio, E., Calhoun, K. E., Daly, M. B., Farrar, W. B., Garber, J. E., Gray, R., Greenberg, C. C., Greenup, R., Hansen, N., Hill-Kayser, C., Hudis, C., Khakpour, N., Kirstein, L., Laronga, C., Leitch, A. M., Lynce, F., Mahoney, M. C., … Ward, J. H. (2018). Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 16(11), 1362-1389.  https://academic.oup.com/jbi/article/6/1/4/7505060

6.  Hodgson, D. C. (2011). Late effects in the setting of Hodgkin lymphoma. Hematology/Oncology Clinics of North America, 25(1), 179-202.  https://pmc.ncbi.nlm.nih.gov/articles/PMC2857928

7.  Sprague, B. L., Gangnon, R. E., Burt, V., Trentham-Dietz, A., Hampton, J. M., Wellman, R. D., Kerlikowske, K., & Miglioretti, D. L. (2014). Prevalence of mammographically dense breasts in the United States. JNCI: Journal of the National Cancer Institute, 106(10), dju255.  https://pubmed.ncbi.nlm.nih.gov/25217577/

8.  U.S. Food and Drug Administration. (2023). FDA updates mammography regulations to require reporting of breast density information and enhance facility oversight. FDA.  https://www.fda.gov/news-events/press-announcements/fda-updates-mammography-regulations-require-reporting-breast-density-information-and-enhance

9.  American Cancer Society. (2024). Survival rates for breast cancer.  https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html

10.  American Cancer Society. (2024). Can I lower my risk of breast cancer?  https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/can-i-lower-my-risk.html

11.  Pizot, C., Boniol, M., Mullie, P., Koechlin, A., Boniol, M., Boyle, P., & Autier, P. (2016). Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. European Journal of Cancer, 52, 138-154.  https://pubmed.ncbi.nlm.nih.gov/26687833/

12.  Anstey, E. H., Shoemaker, M. L., Barrera, C. M., O’Neil, M. E., Verma, A. B., & Holman, D. M. (2017). Breastfeeding and breast cancer risk reduction: Implications for black mothers. American Journal of Preventive Medicine, 53(3S1), S40-S46.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518059/

13.  Collaborative Group on Hormonal Factors in Breast Cancer. (2019). Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet, 394(10204), 1159-1168.  https://www.ajmc.com/view/hrt-associated-with-higher-breast-cancer-risk

14.  Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., Hurria, A., Marks, L. B., LaMonte, S. J., Warner, E., Lyman, G. H., & Ganz, P. A. (2016). American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. CA: A Cancer Journal for Clinicians, 66(1), 43-73.  https://pmc.ncbi.nlm.nih.gov/articles/PMC3744245


Megha Shah, DNP, APRN, FNP-BC, OCN, an oncology nurse practitioner with over 16 years of clinical experience in cancer care wrote this article. It is for educational purposes only and does not constitute individualized medical advice. Speak with your healthcare provider about screening schedules and risk factors specific to your health history. | meghashah.me

Be the First to Comment